person · Reporting owner

Chin Mark

Disclosed activity across 5 companies

Tapewire entity: 36001
SEC CIK: 0001734389

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Disc Medicine, Inc.IRON · Entity 2273	Director	June 18, 2026	June 23, 2026
Enliven Therapeutics, Inc.IMRA · Entity 4024	Director	June 02, 2022	June 04, 2022
Iterum Therapeutics plcITRM · Entity 72802	Director	June 15, 2023	June 15, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Disc Medicine, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2036-06-17	Direct	6,212	Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 6,212 · Balance 6,212 F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Enliven Therapeutics, Inc.

Report date June 02, 2022 · Filed June 04, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2032-06-01	Direct	8,500	Reported balance After 2022-06-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-06-02 · Grant · Acquired 8,500 · Balance 8,500 F2: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant.
Common StockSEC Table I · non-derivative	IndirectBy entities affiliated with Arix Bioscience plc	2,344,072	Reported balance Holding disclosure · report date 2022-06-02 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,344,072 F1: The shares are directly beneficially owned by Arix Bioscience Holdings Limited ("Arix Ltd."). Arix Bioscience Plc ("Arix Plc") is the sole owner and parent of Arix Ltd. and may be deemed to indirectly beneficially own the shares held by Arix Ltd. Mr. Chin is a managing director of Arix plc. Each of Arix plc and Mr. Chin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are directly beneficially owned by Arix Bioscience Holdings Limited ("Arix Ltd."). Arix Bioscience Plc ("Arix Plc") is the sole owner and parent of Arix Ltd. and may be deemed to indirectly beneficially own the shares held by Arix Ltd. Mr. Chin is a managing director of Arix plc. Each of Arix plc and Mr. Chin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

F2: The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant.

Iterum Therapeutics plc

Report date June 15, 2023 · Filed June 15, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	18,306	Reported balance After 2023-06-15 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2023-06-15 · Exercise / conversion · Acquired 15,853 · Balance 18,306 F1: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F2: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-06-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-06-15 · Exercise / conversion · Disposed 15,853 · Balance 0 F1: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F3: On June 15, 2022, the reporting person was granted an award of 15,853 RSUs, which vested in full on June 15, 2023. F2: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

F2: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split.

F3: On June 15, 2022, the reporting person was granted an award of 15,853 RSUs, which vested in full on June 15, 2023.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Harpoon Therapeutics, Inc.

Report date March 08, 2024 · Filed March 11, 2024

Section 16 reporting ended · disclosed 2024-03-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2024-03-11 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-03-08 · Grant · Acquired 424 · Balance 13,224 F1: Represents shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") issuable upon the settlement of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of prorated retainer fees totaling $9,753.00 for the first quarter of 2024. Row 2 · 2024-03-11 · Disposition to issuer · Disposed 13,224 · Balance 0 F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F3: Includes 13,224 RSUs which are subject to rounding as a result of the 1:10 reverse stock split effective September 1, 2023. F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration").
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.15	Direct	Reported balance After 2024-03-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-03-11 · Disposition to issuer · Disposed 2,033 · Balance 0 F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F7: (Continued from footnote 6) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.10	Direct	Reported balance After 2024-03-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-03-11 · Disposition to issuer · Disposed 1,016 · Balance 0 F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F7: (Continued from footnote 6) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.10	Direct	Reported balance After 2024-03-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-03-11 · Disposition to issuer · Disposed 3,214 · Balance 0 F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F7: (Continued from footnote 6) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.66	Direct	Reported balance After 2024-03-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-03-11 · Disposition to issuer · Disposed 2,300 · Balance 0 F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F7: (Continued from footnote 6) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") issuable upon the settlement of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of prorated retainer fees totaling $9,753.00 for the first quarter of 2024.

F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger").

F3: Includes 13,224 RSUs which are subject to rounding as a result of the 1:10 reverse stock split effective September 1, 2023.

F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration").

F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the

F7: (Continued from footnote 6) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.

Pyxis Oncology, Inc.

Report date April 21, 2022 · Filed April 25, 2022

Section 16 reporting ended · disclosed 2022-04-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2022-04-21 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2022-04-21 · Sale · Disposed 1,745,761 · Balance 0 F1: The securities were held directly by Arix Bioscience Holdings Limited ("Arix"). The Reporting Person is one of for members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities were held directly by Arix Bioscience Holdings Limited ("Arix"). The Reporting Person is one of for members of the Investment Committee of Arix and, in such capacity, may be deemed to share voting and dispositive power over the securities held by Arix. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his respective pecuniary interests therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 17, 2019 Filed Dec 18, 2019 02:23 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon Stock	12,476	$16.83	$209,968.58	Disclosure SEC source: 0001209191-19-061059 · doc4.xml · nonDerivative · entry 3 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Limited Disclosed balance after: 2,572,359 F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $16.80 to $17.00 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited. Read SEC document
December 16, 2019 Filed Dec 18, 2019 02:23 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon Stock	13,080	$17.02	$222,680.46	Disclosure SEC source: 0001209191-19-061059 · doc4.xml · nonDerivative · entry 2 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Limited Disclosed balance after: 2,584,835 F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $17.00 to $17.28 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited. Read SEC document
December 13, 2019 Filed Dec 18, 2019 02:23 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon Stock	11,002	$17.21	$189,341.12	Disclosure SEC source: 0001209191-19-061059 · doc4.xml · nonDerivative · entry 1 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Limited Disclosed balance after: 2,597,915 F1 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $17.00 to $17.68 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited. Read SEC document
December 10, 2019 Filed Dec 11, 2019 01:07 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon Stock	131,696	$16.91	$2,227,018.87	Disclosure SEC source: 0001209191-19-059954 · doc4.xml · nonDerivative · entry 4 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Limited Disclosed balance after: 2,608,917 F1 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited. Read SEC document
December 09, 2019 Filed Dec 11, 2019 01:07 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon Stock	77,316	$18.12	$1,400,664.39	Disclosure SEC source: 0001209191-19-059954 · doc4.xml · nonDerivative · entry 3 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Limited Disclosed balance after: 2,740,613 F1 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited. Read SEC document
December 09, 2019 Filed Dec 11, 2019 01:07 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon Stock	26,438	$18.30	$483,781.03	Disclosure SEC source: 0001209191-19-059954 · doc4.xml · nonDerivative · entry 2 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Limited Disclosed balance after: 2,817,929 F1 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited. Read SEC document
December 06, 2019 Filed Dec 11, 2019 01:07 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	SaleCommon Stock	47,752	$19.15	$914,221.59	Disclosure SEC source: 0001209191-19-059954 · doc4.xml · nonDerivative · entry 1 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Limited Disclosed balance after: 2,844,367 F1 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited. Read SEC document
June 13, 2019 Filed Jun 17, 2019 21:00 UTC	Iterum Therapeutics plc ITRM · Entity 72802	GrantRestricted Stock Units · Derivative	5,703	$0.00	$0.00	Disclosure SEC source: 0000899243-19-017200 · doc4.xml · derivative · entry 1 Chin Mark · CIK 0001734389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,703 Underlying: Ordinary Shares · 5,703 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU. F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Equity Incentive Plan, the RSUs shall vest on June 13, 2020. F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Equity Incentive Plan, the RSUs shall vest on June 13, 2020. Read SEC document
June 03, 2019 Filed Jun 5, 2019 21:17 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	GrantDirector Stock Option (Right to Buy) · Derivative	10,167	$0.00 Strike: $11.84	$0.00	Disclosure SEC source: 0001209191-19-034836 · doc4.xml · derivative · entry 1 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2029-06-02 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on June 3, 2020, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document
May 24, 2019 Filed May 29, 2019 20:22 UTC	Iterum Therapeutics plc ITRM · Entity 72802	Exercise / conversionRestricted Stock Units · Derivative	6,154	$0.00	$0.00	Disclosure SEC source: 0000899243-19-015014 · doc4.xml · derivative · entry 3 Chin Mark · CIK 0001734389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units. F3 · derivative.exercise_date: On May 24, 2018, the reporting person was granted an award of 6,154 restricted stock units, which vested on May 24, 2019. F3 · derivative.expiration_date: On May 24, 2018, the reporting person was granted an award of 6,154 restricted stock units, which vested on May 24, 2019. Read SEC document
May 24, 2019 Filed May 29, 2019 20:22 UTC	Iterum Therapeutics plc ITRM · Entity 72802	Exercise / conversionOrdinary Shares	6,154	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-015014 · doc4.xml · nonDerivative · entry 1 Chin Mark · CIK 0001734389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units. Read SEC document
February 12, 2019 Filed Feb 14, 2019 22:24 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	ConversionSeries C Preferred Stock · Derivative	742,850	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-010297 · doc4.xml · derivative · entry 7 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Limited Disclosed balance after: 0 Underlying: Common Stock · 742,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited. Read SEC document
February 12, 2019 Filed Feb 14, 2019 22:24 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	ConversionSeries B Preferred Stock · Derivative	1,720,698	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-010297 · doc4.xml · derivative · entry 6 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Limited Disclosed balance after: 0 Underlying: Common Stock · 1,720,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited. Read SEC document
February 12, 2019 Filed Feb 14, 2019 22:24 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	PurchaseCommon Stock	428,571	$14.00	$5,999,994.00	Disclosure SEC source: 0001209191-19-010297 · doc4.xml · nonDerivative · entry 3 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Limited Disclosed balance after: 2,892,119 F2 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited. Read SEC document
February 12, 2019 Filed Feb 14, 2019 22:24 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	ConversionCommon Stock	742,850	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-010297 · doc4.xml · nonDerivative · entry 2 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Limited Disclosed balance after: 2,463,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited. Read SEC document
February 12, 2019 Filed Feb 14, 2019 22:24 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	ConversionCommon Stock	1,720,698	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-010297 · doc4.xml · nonDerivative · entry 1 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Limited Disclosed balance after: 1,720,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited. Read SEC document
February 07, 2019 Filed Mar 29, 2019 20:16 UTC Amendment	Harpoon Therapeutics, Inc. HARP · Entity 11424	GrantDirector Stock Option (Right to Buy) · Derivative	6,071	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0001209191-19-021730 · doc4a.xml · derivative · entry 1 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,071 Underlying: Common Stock · 6,071 shares Expires 2029-02-06 F1 · shares: This stock option, which was granted on February 7, 2019, was omitted from the Reporting Person's original Form 4. F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the last day of each calendar quarter following the grant date of February 7, 2019 (on March 31, 2019, June 30, 2019, September 30, 2019, and December 31, 2019), subject to the continuous service of the Reporting Person on each vesting date. Read SEC document
December 19, 2018 Filed Feb 14, 2019 22:24 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	GrantDirector Stock Option (Right to Buy) · Derivative	20,335	$0.00 Strike: $2.12	$0.00	Disclosure SEC source: 0001209191-19-010297 · doc4.xml · derivative · entry 5 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,335 Underlying: Common Stock · 20,335 shares Expires 2028-12-19 F3 · kind: Reflects a transaction with the Issuer prior to its Section 12 registration which occurred within 6 months of the post-registration transaction reported on this Form 4. F4 · derivative.exercise_date: The stock option vests in three annual installments starting on December 19, 2019, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document
November 09, 2018 Filed Feb 14, 2019 22:24 UTC	Harpoon Therapeutics, Inc. HARP · Entity 11424	PurchaseSeries C Preferred Stock · Derivative	742,850	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-010297 · doc4.xml · derivative · entry 4 Chin Mark · CIK 0001734389 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Limited Disclosed balance after: 742,850 Underlying: Common Stock · 742,850 shares Expires not disclosed F1 · derivative.exercise_price: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F3 · kind: Reflects a transaction with the Issuer prior to its Section 12 registration which occurred within 6 months of the post-registration transaction reported on this Form 4. F1 · price: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience plc, the parent company of Arix Bioscience Holdings Limited. Read SEC document
October 30, 2018 Filed Nov 1, 2018 21:25 UTC	Iterum Therapeutics plc ITRM · Entity 72802	PurchaseOrdinary Shares	58,000	$6.10	$353,800.00	Disclosure SEC source: 0001209191-18-056808 · doc4.xml · nonDerivative · entry 1 Chin Mark · CIK 0001734389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Ltd. Disclosed balance after: 1,089,903 F1 · ownership.nature: The Reporting Person is an Investment Director for Arix Bioscience Holdings Ltd. Read SEC document
May 30, 2018 Filed Jun 1, 2018 19:37 UTC	Iterum Therapeutics plc ITRM · Entity 72802	ConversionSeries B-2 Preferred Shares · Derivative	248,721	$0.00	$0.00	Disclosure SEC source: 0001209191-18-034622 · doc4.xml · derivative · entry 5 Chin Mark · CIK 0001734389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Ltd. Disclosed balance after: 0 Underlying: Ordinary Shares · 248,721 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F3 · derivative.exercise_date: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F4 · derivative.expiration_date: Not applicable. F2 · ownership.nature: The Reporting Person is an Investment Director for By Arix Bioscience Holdings Ltd. Read SEC document
May 30, 2018 Filed Jun 1, 2018 19:37 UTC	Iterum Therapeutics plc ITRM · Entity 72802	ConversionSeries B-1 Preferred Shares · Derivative	445,576	$0.00	$0.00	Disclosure SEC source: 0001209191-18-034622 · doc4.xml · derivative · entry 4 Chin Mark · CIK 0001734389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Ltd. Disclosed balance after: 0 Underlying: Ordinary Shares · 445,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F1 · derivative.exercise_date: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F4 · derivative.expiration_date: Not applicable. F2 · ownership.nature: The Reporting Person is an Investment Director for By Arix Bioscience Holdings Ltd. Read SEC document
May 30, 2018 Filed Jun 1, 2018 19:37 UTC	Iterum Therapeutics plc ITRM · Entity 72802	PurchaseOrdinary Shares	337,606	$13.00	$4,388,878.00	Disclosure SEC source: 0001209191-18-034622 · doc4.xml · nonDerivative · entry 3 Chin Mark · CIK 0001734389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Ltd. Disclosed balance after: 1,031,903 F2 · ownership.nature: The Reporting Person is an Investment Director for By Arix Bioscience Holdings Ltd. Read SEC document
May 30, 2018 Filed Jun 1, 2018 19:37 UTC	Iterum Therapeutics plc ITRM · Entity 72802	ConversionOrdinary Shares	248,721	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-034622 · doc4.xml · nonDerivative · entry 2 Chin Mark · CIK 0001734389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Ltd. Disclosed balance after: 694,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F2 · ownership.nature: The Reporting Person is an Investment Director for By Arix Bioscience Holdings Ltd. Read SEC document
May 30, 2018 Filed Jun 1, 2018 19:37 UTC	Iterum Therapeutics plc ITRM · Entity 72802	ConversionOrdinary Shares	445,576	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-034622 · doc4.xml · nonDerivative · entry 1 Chin Mark · CIK 0001734389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Arix Bioscience Holdings Ltd. Disclosed balance after: 445,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F2 · ownership.nature: The Reporting Person is an Investment Director for By Arix Bioscience Holdings Ltd. Read SEC document
May 24, 2018 Filed May 29, 2018 21:24 UTC	Iterum Therapeutics plc ITRM · Entity 72802	GrantRestricted Stock Units · Derivative	6,154	$0.00	$0.00	Disclosure SEC source: 0001209191-18-033907 · doc4.xml · derivative · entry 1 Chin Mark · CIK 0001734389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,154 Underlying: Ordinary Shares · 6,154 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Ordinary Shares. F2 · derivative.exercise_date: Subject to the Reporting Person providing continuous service, the RSU shall vest on May 24, 2019. F2 · derivative.expiration_date: Subject to the Reporting Person providing continuous service, the RSU shall vest on May 24, 2019. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.